Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cmab809
- Development stage
- Phase 1
- Lead developer
- Taizhou Mabtech Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CMAB809 is a biosimilar of trastuzumab, developed as a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). It acts as an antagonist to the ERBB2 (HER2) receptor and exerts its antitumor effects through inhibition of HER2-mediated signaling and by inducing antibody-dependent cell-mediated cytotoxicity (ADCC). The drug is intended for intravenous administration. Its primary indications are for the adjuvant treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. CMAB809 was developed by Taizhou Mabtech Pharmaceutical Co., Ltd. and has completed phase 1 clinical trials in healthy volunteers and patients with breast cancer[1][2][3][5].
- Other names
- trastuzumab biosimilar
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on cmab809.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cmab809.